Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, B-Cell 1

Interventions

Cyclophosphamide 16fludarabine 12Rituximab 4Antigens, CD19 4Lenalidomide 3Immunotherapy, Adoptive 3Etoposide 3orelabrutinib 2Nivolumab 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Methotrexate 2zanubrutinib 1relmacabtagene autoleucel 1prednylidene 1obinutuzumab 1merphos 1ixazomib 1gemcitabine-oxaliplatin regimen 1fludarabine phosphate 1entecavir 1eltrombopag 1deltacortene 1abivertinib 1Vincristine 1Transplantation, Autologous 1Tenofovir 1Prednisone 1Pentostatin 1Melphalan 1Interleukin-7 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Lymphoma, B-Cell × Interleukin-7 × Clear all
NCT03929107 2019-04-26

Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T for Refractory/Relapsed B Cell Lymphoma.

First Affiliated Hospital of Zhejiang University

Phase 2 Unknown
80 enrolled
Lymphoid

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡